Dusseldorf - Delayed Quote EUR

Eli Lilly and Co (LLY0.DU)

17.40

-0.10

(-0.57%)

As of 4:31:13 PM GMT+2. Market Open.

Healthcare worst-performing S&P subsector YTD: Mizuho expert

Tariffs, executive orders, and FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's actions are pressuring a historically "safe" sector.

Yahoo Finance 1 hour ago

^GSPC

UNH

LLY
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Yahoo Finance 3 hours ago

NONOF

NVO

LXRX
These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Axon Tops Buy Point

As the stock market extends its rebound, it's important to watch the stocks most loved among equity analysts. Netflix and Visa are two of the seven best stocks where investors can find magnificent profit growth prospects. Of 54 analysts covering Netflix, 38 have buy or overweight ratings on the video streaming service.

Investor's Business Daily 5 hours ago

AXON

ISRG

LLY
How Hims & Hers survived the great Spac shakeout

About five years ago, special purpose acquisition companies — or Spacs — were all the rage in the US. Start-ups light years away from profitability...

PREMIUM
Financial Times yesterday

HIMS

NONOF

NVO
Trump's drug price order is part request, part threat: Analyst

President Trump signed an executive order on Monday calling for pharmaceutical companies to cut their drug prices for US consumers. Bernstein Senior Analyst, US Biopharmaceuticals Courtney Breen comments on whether the Trump administration ultimately has the power to force drug companies to do this. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video yesterday

LLY

ABBV

AMGN
S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Investor's Business Daily yesterday

NONOF

NVO

AMGN
How Trump could go about executing order to slash drug prices

President Trump signed an executive order on Monday asking drugmakers to cut prices on their prescription drugs. Yahoo Finance consumer affairs reporter Jordan Weissmann reviews Trump's latest push to slash drug costs and how the administration may seek to go about it. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video yesterday

MRK

AMGN

ABBV
Eli Lilly (NYSE:LLY) Announces Superior Weight Loss Results for Zepbound Over Wegovy

Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside its participation at the European Congress on Obesity and publication in The New England Journal of Medicine. Despite these headline-grabbing results, Eli Lilly's stock movement remained flat over the last month, aligning with broader market trends, which also showed little change. The...

Simply Wall St. yesterday

LLY
Fox One, SoftBank delays investment, Zepbound weight loss

Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including Fox's (FOX, FOXA) new streaming service, Fox One; SoftBank (9434.T) delaying its $100 billion investment into AI infrastructure in the US; and patients using Eli Lilly's (LLY) Zepbound reporting losing more weight than Novo Nordisk's (NVO) Wegovy GLP-1 weight-loss drug. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 2 days ago

FOX

FOXA

NONOF
Trump expected to sign order to slash US drug prices

President Trump is expected to sign an executive order intended to cut US prescription drug prices in order to match drug prices overseas. Yahoo Finance senior health reporter Anjalee Khemlani outlines the many steps and government agencies involved in investigating and carrying out this act. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 2 days ago

NONOF

NVO

GILD
Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers

The "Magnificent Seven," made up of Nvidia (NVDA), Alphabet (GOOG, GOOGL), Tesla (TSLA), Microsoft (MSFT), Amazon (AMZN), Meta (META), and Apple (AAPL), are rallying after the US and China agreed to lower tariff rates for a 90-day period. Airline stocks, like American Airlines (AAL), Delta (DAL), and United Airlines (UAL), are also gaining on the trade deal. Pharmacy stocks, including Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck (MRK), are moving to the downside after US President Trump said he will cut drug prices by over 50%. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 2 days ago

GOOG

MSFT

UAL
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

The Wall Street Journal 2 days ago

LLY
US-China trade truce, April CPI, drug prices: 3 Things

US stock futures (ES=F, NQ=F, YM=F) are surging Monday morning after US and China officials agreed to significant cuts to each country's respective tariff rates in a 90-day cool-off period. April's Consumer Price Index (CPI) is due out tomorrow, reporting month-over-month trends in US inflation rates. President Trump vows to cut prescription drug prices by as much as 80%. In turn, pharmaceutical stocks are seeing across the board pullbacks in pre-market trading. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 2 days ago

ES=F

PFE

JNJ
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?NYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits Trum

Bloomberg 2 days ago

AZN

AZNCF

BERZ
Trending tickers: Tesla, Alibaba, Eli Lilly, Novo Nordisk and Glencore

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 2 days ago

RGTI

RGTIW

BABA
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg 2 days ago

C

TAK

TKPHF
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, Zepbound met the primary endpoint and all five key secondary endpoints, demonstrati

PR Newswire 2 days ago

LLY
Wall Street Brings the Bitcoin-Versus-Gold Clash to ETF Masses

(Bloomberg) -- The culture clash between Bitcoin enthusiasts and gold bugs is about to be played out in the world of exchange-traded funds.Most Read from BloombergIs Trump’s Plan to Reopen the Notorious Alcatraz Prison Realistic?As Trump Reshapes Housing Policy, Renters Face Rollback of RightsVail to Borrow Muni Debt to Ease Ski Resort Town Housing CrunchNYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Tidal Fina

Bloomberg 5 days ago

F

COIN

TSLA
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.

PR Newswire 5 days ago

LLY
Eli Lilly (NYSE:LLY) Announces Executive Changes To Drive Global Growth And Pipeline Advancement

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and Kenneth Custer, marking a strategic shift aiming to expand its global market presence and enhance product reach. Over the past month, the company's stock appreciated by 7%, potentially reflecting investor confidence in its direction amid these changes. Strong quarterly financial results, with significant increases in sales and earnings, would have bolstered investor...

Simply Wall St. 5 days ago

LLY

Performance Overview

Return	LLY0.DU	S&P 500 (^GSPC)
YTD	-2.79%	+0.13%
1-Year	-5.97%	+12.24%
3-Year	-7.94%	+46.35%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Co (LLY0.DU)

Healthcare worst-performing S&P subsector YTD: Mizuho expert

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna

These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Axon Tops Buy Point

How Hims & Hers survived the great Spac shakeout

Trump's drug price order is part request, part threat: Analyst

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

How Trump could go about executing order to slash drug prices

Eli Lilly (NYSE:LLY) Announces Superior Weight Loss Results for Zepbound Over Wegovy

Fox One, SoftBank delays investment, Zepbound weight loss

Trump expected to sign order to slash US drug prices

Mag 7 rally, airline & pharmaceutical stocks: Trending Tickers

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

US-China trade truce, April CPI, drug prices: 3 Things

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Trending tickers: Tesla, Alibaba, Eli Lilly, Novo Nordisk and Glencore

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Wall Street Brings the Bitcoin-Versus-Gold Clash to ETF Masses

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Eli Lilly (NYSE:LLY) Announces Executive Changes To Drive Global Growth And Pipeline Advancement

Performance Overview